Depression | Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning
Depression research study
What is the primary objective of this study?
To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning).
Who is eligible to participate?
Inclusion Criteria: 1. Eligible patients were enrolled in the clinical trials program of hte Samsung Medical Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the Korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, Fourth edition. 2. interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians Exclusion Criteria: 1. received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks 2. potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Continuous Antidepressant Abuse
Adverse Reaction to Drug
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:EscitalopramAntidepressant administration of Escitalopram for 8 weeks under therapeutic dose
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Antidepressant treated groupAntidepressant treated group: depressed patients treated with Escitalopram
other antidepressant treated groupother Antidepressant treated group: depressed patients treated with other antidepressant without escitalopram
Start Date: December 2008
Completed Date: December 2016
Primary Outcome: antidepressant response at 2,4,6,8 weeks A/E monitoring at 1,2,4,6,8 weeks
Secondary Outcome: biological value at 0 week and 8 weeks
Study sponsors, principal investigator, and references
Principal Investigator: Doh Kwan Kim, PhD, M.D.
Lead Sponsor: Samsung Medical Center
Collaborator: H. Lundbeck A/S